There are several possible explanations for this, but a prominent one is a failure of current parenterally delivered pertussis vaccines to induce mucosal immunity, including induction of IgA and TRM cells in the respiratory tract, which provide the first line of defense against re-infection of mucosal surfaces. Here, CD79A is linked to pertussis.